- ￥2310 - 21520
- Sino Biological
- 北京
- 10004-H08H
- 2026年01月26日
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
-20℃ to -80℃
- 保质期：
12个月
- 英文名：
Recombinant Human HER2 / ErbB2 Protein (His Tag)
- 库存：
99
- 供应商：
北京义翘神州科技股份有限公司
- 规格：
1.00 mg/50.00 µg/100.00 µg
| 规格： | 1.00 mg | 产品价格： | ￥21520.0 |
|---|---|---|---|
| 规格： | 50.00 µg | 产品价格： | ￥2310.0 |
| 规格： | 100.00 µg | 产品价格： | ￥3310.0 |
重组人 HER2 / ErbB2 蛋白 (His标签)（产品说明）
蛋白名称：Human HER2 / ErbB2 Protein (His Tag)
蛋白构建：A DNA sequence encoding the extracellular domain (Met 1-Thr 652) of human ErbB2 (NP_004439.2) was fused with the polyhistidine tag at the C-terminus.
表达宿主：HEK293 Cells
蛋白纯度：> 90 % as determined by SDS-PAGE
蛋白活性：1. Measured by its binding ability in a functional ELISA. Immobilized human Erbb2 at 2.5 μg/ml (100 μl/well) can bind Herceptin with a linear range of 1.28-32 ng/ml. 2. Measured by its ability to block anti-ErbB2 mediated inhibition of BT474 human breast ductal carcinoma cell proliferation. The ED50 for this effect is 0.2-1 μg/mL in the presence of 0.6 µg/mL Anti-ErbB2/Her2 Monoclonal Antibody. 3. Using the Octet RED System, the affinity constant (Kd) of Her2 / ERBB2 Protein, Human, Recombinant (His Tag) (Cat: 10004-H08H) bound to Pertuzumab was 0.1 nM.
蛋白内毒素：< 1.0 EU per μg of the protein as determined by the LAL method
预测N端：Thr 23
蛋白分子量：The recombinant human ErbB2 comprises 641 amino acids and has a calculated molecular mass of 71 kDa. As a result of glycosylation, rh ErbB2 migrates as an approximately 100-110 kDa protein in SDS-PAGE under reducing conditions.
蛋白NP号：NP_004439.2
蛋白氨基酸序列：Met1-Thr652
蛋白标签：C-His
蛋白保存条件：Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
蛋白名称：Human HER2 / ErbB2 Protein (His Tag)
蛋白构建：A DNA sequence encoding the extracellular domain (Met 1-Thr 652) of human ErbB2 (NP_004439.2) was fused with the polyhistidine tag at the C-terminus.
表达宿主：HEK293 Cells
蛋白纯度：> 90 % as determined by SDS-PAGE
蛋白活性：1. Measured by its binding ability in a functional ELISA. Immobilized human Erbb2 at 2.5 μg/ml (100 μl/well) can bind Herceptin with a linear range of 1.28-32 ng/ml. 2. Measured by its ability to block anti-ErbB2 mediated inhibition of BT474 human breast ductal carcinoma cell proliferation. The ED50 for this effect is 0.2-1 μg/mL in the presence of 0.6 µg/mL Anti-ErbB2/Her2 Monoclonal Antibody. 3. Using the Octet RED System, the affinity constant (Kd) of Her2 / ERBB2 Protein, Human, Recombinant (His Tag) (Cat: 10004-H08H) bound to Pertuzumab was 0.1 nM.
蛋白内毒素：< 1.0 EU per μg of the protein as determined by the LAL method
预测N端：Thr 23
蛋白分子量：The recombinant human ErbB2 comprises 641 amino acids and has a calculated molecular mass of 71 kDa. As a result of glycosylation, rh ErbB2 migrates as an approximately 100-110 kDa protein in SDS-PAGE under reducing conditions.
蛋白NP号：NP_004439.2
蛋白氨基酸序列：Met1-Thr652
蛋白标签：C-His
蛋白保存条件：Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验该产品被引用文献
1, Gilabert-Oriol, R; et al. Modified trastuzumab and cetuximab mediate efficient toxin delivery while retaining antibody-dependent cell-mediated cytotoxicity in target cells. Molecular pharmaceutics, PMID: 24050452
2, Eletxigerra, U; et al. Surface plasmon resonance immunosensor for ErbB2 breast cancer biomarker determination in human serum and raw cancer cell lysates. Analytica chimica acta, PMID: 26755150
3, Lombana, TN; et al. High-resolution glycosylation site-engineering method identifies MICA epitope critical for shedding inhibition activity of anti-MICA antibodies. mAbs, PMID: 30307368
4, Murakami, S; et al. Constructive approach for synthesis of a functional IgG using a reconstituted cell-free protein synthesis system. Scientific reports, PMID: 30679500
5, Hartmann, L; et al. VHH characterization. Comparison of recombinant with chemically synthesized anti-HER2 VHH. Protein science : a publication of the Protein Society, PMID: 31423659
6, Kim, J; et al. Labeling-free detection of ECD-HER2 protein using aptamer-based nano-plasmonic sensor. Nanotechnology, PMID: 31914433
7, Leeman, M; et al. Asymmetric flow field-flow fractionation coupled to surface plasmon resonance detection for analysis of therapeutic proteins in blood serum. Analytical and bioanalytical chemistry, PMID: 33098467
8, Park, HJ; et al. One-pot colorimetric detection of molecules based on proximity proteolysis reaction. Biosensors & bioelectronics, PMID: 34030090
9, Chabrol, E; et al. Biochemistry, structure, and cellular internalization of a four nanobody-bearing Fc dimer. Protein science : a publication of the Protein Society, PMID: 34117809
10, Huo, Y; et al. M1 polarization enhances the antitumor activity of chimeric antigen receptor macrophages in solid tumors. Journal of translational medicine, PMID: 36978075
11, Koga, H; et al. Rapid Generation of Murine Bispecific Antibodies Using FAST-IgTM for Preclinical Screening of HER2/CD3 T-Cell Engagers. Antibodies (Basel, Switzerland), PMID: 38247567 1
2, Long, AW; et al. Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma. Journal of hematology & oncology, PMID: 38650005 1
3, McCue, AC; et al. Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy. mAbs, PMID: 38962811 1
4, Fournier, L; et al. Discovery of potent allosteric antibodies inhibiting EGFR. mAbs, PMID: 39304998 1
5, Pierini, S; et al. Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models. Nature communications, PMID: 39814734 1
6, Reiss, KA; et al. CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial. Nature medicine, PMID: 39920391 1
7, Westerberg, C; et al. Affibody-based HER2 prodrug shows conditional cytotoxic effect on HER2-positive cancer cells. Biochemical and biophysical research communications, PMID: 40117970 1
8, Zhang, M; et al. A new strategy to HER2-specific antibody discovery through artificial intelligence-powered phage display screening based on the Trastuzumab framework. Biochimica et biophysica acta. Molecular basis of disease, PMID: 40056877 1
9, Ahn, D; et al. Enhanced Targeted Drug Delivery System to Control Avidity and Drug Encapsulation Using E2 Nanocages and SpyTag/SpyCatcher. ACS biomaterials science & engineering, PMID: 40209085
20, Tsao, LC; et al. Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd). Nature communications, PMID: 40175391
21, Wang, Y; et al. Intrinsic/proximal cell surface marker logic-gated extracellular targeted protein degradation in specific cell population. Molecular therapy : the journal of the American Society of Gene Therapy, PMID: 40340249
2, Eletxigerra, U; et al. Surface plasmon resonance immunosensor for ErbB2 breast cancer biomarker determination in human serum and raw cancer cell lysates. Analytica chimica acta, PMID: 26755150
3, Lombana, TN; et al. High-resolution glycosylation site-engineering method identifies MICA epitope critical for shedding inhibition activity of anti-MICA antibodies. mAbs, PMID: 30307368
4, Murakami, S; et al. Constructive approach for synthesis of a functional IgG using a reconstituted cell-free protein synthesis system. Scientific reports, PMID: 30679500
5, Hartmann, L; et al. VHH characterization. Comparison of recombinant with chemically synthesized anti-HER2 VHH. Protein science : a publication of the Protein Society, PMID: 31423659
6, Kim, J; et al. Labeling-free detection of ECD-HER2 protein using aptamer-based nano-plasmonic sensor. Nanotechnology, PMID: 31914433
7, Leeman, M; et al. Asymmetric flow field-flow fractionation coupled to surface plasmon resonance detection for analysis of therapeutic proteins in blood serum. Analytical and bioanalytical chemistry, PMID: 33098467
8, Park, HJ; et al. One-pot colorimetric detection of molecules based on proximity proteolysis reaction. Biosensors & bioelectronics, PMID: 34030090
9, Chabrol, E; et al. Biochemistry, structure, and cellular internalization of a four nanobody-bearing Fc dimer. Protein science : a publication of the Protein Society, PMID: 34117809
10, Huo, Y; et al. M1 polarization enhances the antitumor activity of chimeric antigen receptor macrophages in solid tumors. Journal of translational medicine, PMID: 36978075
11, Koga, H; et al. Rapid Generation of Murine Bispecific Antibodies Using FAST-IgTM for Preclinical Screening of HER2/CD3 T-Cell Engagers. Antibodies (Basel, Switzerland), PMID: 38247567 1
2, Long, AW; et al. Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma. Journal of hematology & oncology, PMID: 38650005 1
3, McCue, AC; et al. Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy. mAbs, PMID: 38962811 1
4, Fournier, L; et al. Discovery of potent allosteric antibodies inhibiting EGFR. mAbs, PMID: 39304998 1
5, Pierini, S; et al. Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models. Nature communications, PMID: 39814734 1
6, Reiss, KA; et al. CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial. Nature medicine, PMID: 39920391 1
7, Westerberg, C; et al. Affibody-based HER2 prodrug shows conditional cytotoxic effect on HER2-positive cancer cells. Biochemical and biophysical research communications, PMID: 40117970 1
8, Zhang, M; et al. A new strategy to HER2-specific antibody discovery through artificial intelligence-powered phage display screening based on the Trastuzumab framework. Biochimica et biophysica acta. Molecular basis of disease, PMID: 40056877 1
9, Ahn, D; et al. Enhanced Targeted Drug Delivery System to Control Avidity and Drug Encapsulation Using E2 Nanocages and SpyTag/SpyCatcher. ACS biomaterials science & engineering, PMID: 40209085
20, Tsao, LC; et al. Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd). Nature communications, PMID: 40175391
21, Wang, Y; et al. Intrinsic/proximal cell surface marker logic-gated extracellular targeted protein degradation in specific cell population. Molecular therapy : the journal of the American Society of Gene Therapy, PMID: 40340249
相关实验
HIS 标签蛋白纯化效果不理想，宝宝心里苦呀。今天，小编来跟大家一起找找原因。 纯化所得组分中没有收集到重组的 HIS 标签蛋白。该问题主要可以分为以下两个方面： 1、HIS 标签蛋白没有结合到填料上就流穿了 原因一 超声的功率不对。超声功率过高，容易导致蛋白炭化；功率过低，蛋白释放不出来。 建议 改变超声功率，同时可以在超声前加入溶菌酶。 原因二 结合缓冲液条件不合适。 建议 检查结合缓冲液中是否有影响结合的因素，如：金属离子螫合剂、强还原剂、过高的咪唑浓度。同时，优化缓冲
蛋白标签（protein tag）是指利用DNA体外重组技术，与目的蛋白一起融合表达的一种多肽或者蛋白，以便于目的蛋白的表达、检测、示踪和纯化等。随着技术的不断发展，研究人员相继开发出了具有各种不同功能的蛋白标签。 一、 新型蛋白标签 蛋白标签应用极为广泛，但仍有两个问题不容忽视：（1）蛋白标签以DNA形式编码，它需要转录并翻译成蛋白后才能发挥作用，而这种作用方式本身就是一种缺陷。例如，常用的荧光蛋白标签，在显微镜下观察时，其显像不如人工合成的荧光基团好，但是这种人工合成的荧
His 标签蛋白纯化效果不理想，宝宝心里苦呀。今天，小编来跟大家一起找找原因。 纯化所得组分中没有收集到重组的His标签蛋白。该问题主要可以分为以下两个方面： 1、His标签蛋白没有结合到填料上就流穿了 原因一 超声的功率不对。超声功率过高，容易导致蛋白炭化；功率过低，蛋白释放不出来。 建议 改变超声功率，同时可以在超声前加入溶菌酶。 原因二 结合缓冲液条件不合适。 建议 检查结合缓冲液中是否有影响结合的因素，如：金属离子螯合剂、强还原剂、过高的咪唑浓度。同时，优化缓冲液的pH、盐
技术资料暂无技术资料 索取技术资料
文献支持
重组人 HER2 / ErbB2蛋白 (His 标签)
￥2310 - 21520
